Bupropion in the treatment of outpatients with asthma and major depressive disorder

E. Sherwood Brown, Lana A. Vornik, David A. Khan, A. John Rush

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Objective: Depressive disorders are common in asthma. Despite the high prevalence, antidepressant therapy in asthma patients with depression remains under-investigated. The objective of this pilot study was to investigate the use of bupropion for depression and anxiety in depressed asthma patients. Method: We conducted a 12-week open-label study of bupropion in 18 depressed asthma patients. Participants were assessed with the Hamilton Rating Scale for Depression (HAM-D-17), Hamilton Rating Scale for Anxiety (HAM-A), Inventory of Depressive Symptomatology - Self-Report (IDS-SR), Asthma Control Questionnaire (ACQ) and spirometry at baseline and weeks 1, 2, 4, 8, and 12. Results: Significant baseline to exit improvements were observed on the HAM-D-17 (mean change = 4.72, SD = 7.78, p = 0.02) and the HAM-A (mean change = 2.12, SD = 3.97, p = 0.04). Based on the HAM-D-17 scores, 27.8% of the patients were responders and 16.7% were remitters. Significant correlations were found between changes in ACQ score and HAM-D-17 r = 0.73, p = 0.001), ACQ score and IDS-SR r = 0.58, p = 0.012), and FEV1% Predicted and HAM-D-17 r = -0.66, p = 0.006). Conclusions: Bupropion treatment was associated with significant improvements in depression and anxiety symptoms in asthma patients. Improvements in asthma correlated significantly with improvements in depression.

Original languageEnglish (US)
Pages (from-to)23-28
Number of pages6
JournalInternational Journal of Psychiatry in Medicine
Volume37
Issue number1
DOIs
StatePublished - 2007

Fingerprint

Bupropion
Major Depressive Disorder
Outpatients
Asthma
Depression
Therapeutics
Anxiety
Self Report
Equipment and Supplies
Spirometry
Depressive Disorder
Antidepressive Agents

Keywords

  • Asthma
  • Bupropion
  • Major depressive disorder

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Bupropion in the treatment of outpatients with asthma and major depressive disorder. / Brown, E. Sherwood; Vornik, Lana A.; Khan, David A.; Rush, A. John.

In: International Journal of Psychiatry in Medicine, Vol. 37, No. 1, 2007, p. 23-28.

Research output: Contribution to journalArticle

@article{f25d7477346b47cc892e59c54ae45a7b,
title = "Bupropion in the treatment of outpatients with asthma and major depressive disorder",
abstract = "Objective: Depressive disorders are common in asthma. Despite the high prevalence, antidepressant therapy in asthma patients with depression remains under-investigated. The objective of this pilot study was to investigate the use of bupropion for depression and anxiety in depressed asthma patients. Method: We conducted a 12-week open-label study of bupropion in 18 depressed asthma patients. Participants were assessed with the Hamilton Rating Scale for Depression (HAM-D-17), Hamilton Rating Scale for Anxiety (HAM-A), Inventory of Depressive Symptomatology - Self-Report (IDS-SR), Asthma Control Questionnaire (ACQ) and spirometry at baseline and weeks 1, 2, 4, 8, and 12. Results: Significant baseline to exit improvements were observed on the HAM-D-17 (mean change = 4.72, SD = 7.78, p = 0.02) and the HAM-A (mean change = 2.12, SD = 3.97, p = 0.04). Based on the HAM-D-17 scores, 27.8{\%} of the patients were responders and 16.7{\%} were remitters. Significant correlations were found between changes in ACQ score and HAM-D-17 r = 0.73, p = 0.001), ACQ score and IDS-SR r = 0.58, p = 0.012), and FEV1{\%} Predicted and HAM-D-17 r = -0.66, p = 0.006). Conclusions: Bupropion treatment was associated with significant improvements in depression and anxiety symptoms in asthma patients. Improvements in asthma correlated significantly with improvements in depression.",
keywords = "Asthma, Bupropion, Major depressive disorder",
author = "Brown, {E. Sherwood} and Vornik, {Lana A.} and Khan, {David A.} and Rush, {A. John}",
year = "2007",
doi = "10.2190/D235-2285-2121-6724",
language = "English (US)",
volume = "37",
pages = "23--28",
journal = "International Journal of Psychiatry in Medicine",
issn = "0091-2174",
publisher = "Baywood Publishing Co. Inc.",
number = "1",

}

TY - JOUR

T1 - Bupropion in the treatment of outpatients with asthma and major depressive disorder

AU - Brown, E. Sherwood

AU - Vornik, Lana A.

AU - Khan, David A.

AU - Rush, A. John

PY - 2007

Y1 - 2007

N2 - Objective: Depressive disorders are common in asthma. Despite the high prevalence, antidepressant therapy in asthma patients with depression remains under-investigated. The objective of this pilot study was to investigate the use of bupropion for depression and anxiety in depressed asthma patients. Method: We conducted a 12-week open-label study of bupropion in 18 depressed asthma patients. Participants were assessed with the Hamilton Rating Scale for Depression (HAM-D-17), Hamilton Rating Scale for Anxiety (HAM-A), Inventory of Depressive Symptomatology - Self-Report (IDS-SR), Asthma Control Questionnaire (ACQ) and spirometry at baseline and weeks 1, 2, 4, 8, and 12. Results: Significant baseline to exit improvements were observed on the HAM-D-17 (mean change = 4.72, SD = 7.78, p = 0.02) and the HAM-A (mean change = 2.12, SD = 3.97, p = 0.04). Based on the HAM-D-17 scores, 27.8% of the patients were responders and 16.7% were remitters. Significant correlations were found between changes in ACQ score and HAM-D-17 r = 0.73, p = 0.001), ACQ score and IDS-SR r = 0.58, p = 0.012), and FEV1% Predicted and HAM-D-17 r = -0.66, p = 0.006). Conclusions: Bupropion treatment was associated with significant improvements in depression and anxiety symptoms in asthma patients. Improvements in asthma correlated significantly with improvements in depression.

AB - Objective: Depressive disorders are common in asthma. Despite the high prevalence, antidepressant therapy in asthma patients with depression remains under-investigated. The objective of this pilot study was to investigate the use of bupropion for depression and anxiety in depressed asthma patients. Method: We conducted a 12-week open-label study of bupropion in 18 depressed asthma patients. Participants were assessed with the Hamilton Rating Scale for Depression (HAM-D-17), Hamilton Rating Scale for Anxiety (HAM-A), Inventory of Depressive Symptomatology - Self-Report (IDS-SR), Asthma Control Questionnaire (ACQ) and spirometry at baseline and weeks 1, 2, 4, 8, and 12. Results: Significant baseline to exit improvements were observed on the HAM-D-17 (mean change = 4.72, SD = 7.78, p = 0.02) and the HAM-A (mean change = 2.12, SD = 3.97, p = 0.04). Based on the HAM-D-17 scores, 27.8% of the patients were responders and 16.7% were remitters. Significant correlations were found between changes in ACQ score and HAM-D-17 r = 0.73, p = 0.001), ACQ score and IDS-SR r = 0.58, p = 0.012), and FEV1% Predicted and HAM-D-17 r = -0.66, p = 0.006). Conclusions: Bupropion treatment was associated with significant improvements in depression and anxiety symptoms in asthma patients. Improvements in asthma correlated significantly with improvements in depression.

KW - Asthma

KW - Bupropion

KW - Major depressive disorder

UR - http://www.scopus.com/inward/record.url?scp=34547611313&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547611313&partnerID=8YFLogxK

U2 - 10.2190/D235-2285-2121-6724

DO - 10.2190/D235-2285-2121-6724

M3 - Article

C2 - 17645195

AN - SCOPUS:34547611313

VL - 37

SP - 23

EP - 28

JO - International Journal of Psychiatry in Medicine

JF - International Journal of Psychiatry in Medicine

SN - 0091-2174

IS - 1

ER -